Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by SizzlinSteakson Mar 19, 2018 4:06pm

345 Views

Post# 27742096

Another Possibility

Possibly an offer on the table pending positive results. Ya never know. I'm sure the pharmeceutical companies have been keeping a close eye on Antibe. The pain killer market is MASSIVE and anything coming along that could potetially replace all existing pain killers would be watched with a very closely I'm sure. It could turn into a bidding war by the big pharmas. I'm sure everyone here would love to see that.

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?